News & Press
GeNeuro: financial information for the first quarter 2022
Geneva, Switzerland, April 15, 2022 – 7.30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 first quarter cash position.
GeNeuro Reports 2021 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 4, 2022 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), reports today its full-year results for the year ended December 31, 2021 and provided a corporate update.
https://geneuro.ch/data/news/2022.04.04-GeNeuro-PR-April-4-2022-FY-2021-results.pdf
ProTEct-MS Phase 2 trial confirms safety of higher doses of temelimab and synergistic potential to address neurodegeneration on top of anti-inflammatory treatment in multiple sclerosis
Geneva, Switzerland, March 21, 2022 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis, today announced that the top-line results of the ProTEct-MS study confirm the excellent safety profile and tolerability of higher doses of temelimab, up to 54mg/kg, used in combination with rituximab, a high-efficacy anti-CD20 drug, thus meeting the primary endpoint of the ProTEct-MS study.
https://geneuro.com/data/news/GeNeuro-MS-Study-topline-results-ENG-March-21-2022.pdf
INTERVIEW : Jesús Martin-Garcia, Président Directeur Général de GeNeuro, revient sur les développements de GeNeuro dans la sclérose en plaques et sur le lien avec le virus d’Epstein-Barr
Genève, Suisse, le 10 mars 2022 – GeNeuro (Euronext Paris : CH0308403085 – GNRO), une société biopharmaceutique développant de nouveaux traitements pour les maladies neurodégénératives et auto-immunes, telles que la sclérose en plaques (SEP), la sclérose latérale amyotrophique (SLA) et les conséquences neuropsychiatriques sévères de COVID-19 (post-COVID), annonce aujourd’hui sa situation de trésorerie au 31 décembre 2021 et fait le point sur ses développements.
GeNeuro announces the completion of its ProTEct-MS study and confirms the March timeline for top-line results, provides a Business Update and Cash Position as of December 31, 2021
Geneva, Switzerland, January 27, 2022 – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today that it has completed its ProTEct-MS clinical trial. The Company also reported its cash position as of December 31, 2021 and provided a business update.
https://geneuro.ch/data/news/2022.01.27-GeNeuro-PR-FY-2021-EN-vf-1-.pdf
Presentation at The Lancet Summit on GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis
Geneva, Switzerland, December 20, 2021 – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled today at the “The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases” additional results from the preclinical research program in Amyotrophic lateral sclerosis (ALS) developed in partnership with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH).
https://geneuro.ch/data/news/2021.12.20-PR-GeNeuro-presentation-at-Lancet-Summit-EN-VF.pdf
GeNeuro receives CHF 6.7 million (EUR 6.4 million) in funding from the Swiss government for the development of temelimab against Long-COVID
Geneva, Switzerland, 13 December 2021, 08:15 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final Phase II results in multiple sclerosis expected in March 2022, announced today that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office of Public Health (FOPH) and that it will receive in this regard a grant of 6.7 million Swiss francs (€6.4 million) to co-fund a Phase 2 clinical trial to treat patients with long-standing COVID who exhibit severe neurological and psychiatric (“neuropsychiatric”) symptoms.
https://geneuro.ch/data/news/GN-PR-FOPH-subsidy-EN-13122021-vf.pdf
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
MS Journal, July 9, 2021
https://geneuro.ch/data/news/MSJ-July-21-Efficacy-and-safety-of-temelimab-in-multiple-sclerosis.pdf
Presentation at American Neurological Association Congress Confirms Potential of GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis
Geneva, Switzerland, 18 October, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that the NINDS, part of the U.S. National Institutes of Health (NIH), presented novel pre-clinical results at the American Neurological Association (ANA) annual meeting, October 17-19, confirming in pre-clinical models of ALS the neurotoxic properties of HERV-K ENV, a retroviral envelope protein encoded by a pathogenic member of the HERV-K family of endogenous human retroviruses, and the therapeutic potential of GeNeuro’s antibody developed to neutralize HERV-K ENV.
https://geneuro.ch/data/news/CP-GeNeuro-PR-NINDS-ALS-ANA-congress-eng-VF.pdf
GeNeuro Reports 2021 Half-Year Results and Provides Corporate Update
Geneva, Switzerland, September 29, 2021 at 7:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2021 and provided a corporate update.
https://geneuro.ch/data/news/GeNeuro-PR-1H2021-Results-ENG-vf.pdf
GeNeuro and Northwestern University enter into a research collaboration on HERV-W ENV in long-haul COVID
Geneva, Switzerland, September 24, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis, announces today that it has entered into a research agreement with Northwestern University to further investigate the relationship between HERV-W ENV (W-ENV) and long-COVID neuropsychiatric syndromes.
https://geneuro.ch/data/news/2021.09.24-GN-PR-NW-agreement-ENG.pdf
GeNeuro announces that a first patient having finished the ProTEct-MS study at the Karolinska Institutet’s Academic Specialist Center has entered the study extension
Geneva, Switzerland, September 21, 2021 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a first patient having completed its ProTEct-MS study at Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm, which tests temelimab at monthly doses of 18, 36 and 54 mg/kg in MS patients, has entered the ProTEct-MS extension
https://geneuro.ch/data/news/GeNeuro-MS-Study-extension-announcement-ENG.pdf